THAC, The Healthy Aging Company, is a French and US-based privately-owned biopharmaceutical company which has the ambition to develop a range of first-in-class drug candidates targeting T2DM and its complications.

♦ Its pipeline could lead to potential real game changers for patient care and disease management.THAC is primarily focused on Type 2 Diabetes Mellitus, a condition with still unmet medical needs.

♦ THAC envisions that by fighting insulin resistance, the root cause of T2DM, major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as peripheral neuropathy (e.g. diabetic foot wounds, amputations).

♦ THAC drug candidates have a unique and innovative mechanism of action that targets oxidation and inflammation.  

♦ THAC drug candidates are intended to delay disease progression, improve patient’s quality of life, delay premature death and prevent T2DM complications ; peripheral neuropathy is a severe complication for which there is no treatment available; e.g., diabetic foot wounds and amputations.

A  Scientific Advisory Board with world renowned leaders in metabolism and diabetes

THAC set up a Strategic Advisory Board (SAB) composed of prominent figures from the academic  world to expand its research and development strategic capabilities.

Members are internationally renowned scientific leaders in metabolism and diabetes, some being consultants for regulatory agencies (US FDA, EU EMA).

The THAC’s team is honored to benefit from their knowledge and fruitfull expertise.

Pr Christophe Magnan is the Chairman of the Scientific Advisory Board.

Prof. Fabrizzio Andreelli, MD, PhD

Professor diabetologist

CHU Pitié-Salpétrière Paris

Head of Department Diabetology

Prof. Jean-François Gautier, MD, PhD

Professor diabeto-endocrino-nutrition

CHU Lariboisière, Paris

Head of Department

Prof. Bernard Thorens, PhD

Professor UNIL Lausanne

University of biology and medicine

Head of GIG department (centre intégratif génomique)

Prof. Robert Eckel, MD, PhD

Professor of Medicine Emeritus

Endocrino-metabolism-diabetes

University Cincinnati, USA

FDA Consultant

Prof. Stefano Del Prato, MD, PhD

Professor endocrinology and

metabolism President EASD

School of Medicine, University Pisa, Italy

Chief of section Diabetes

Pr Agnes Hartemann, PhD, MD

Professor diabetologist CHU Pitié-Salpétrière

Paris, Head of Diabetology Service

Expert diabetic wounds & foots